Seeking Alpha
15 Oct 2026, 03:57 UTC · 2h ago
Repligen: A Buy As Its Growth Engine Gears Up
Impact · against what's priced in
The news is largely neutral to slightly positive as the market has already incorporated the organic growth trends and the BioLife acquisition into the valuation. The primary value lies in the confirmation of a 2027 backlog, reducing the risk of a growth plateau after the 2026 recovery.
- RGEN+0.30
No priced-in read yet
- In context
Repligen's 13% organic growth and the move toward mid-single-digit growth in the Filtration segment by 2026 signal a recovery. The BioLife acquisition provides a high-margin catalyst for EPS accretion.
Read from the article alone
Search tags
